세계의 백신 수탁 제조 시장(2023-2033년)

Vaccine Contract Manufacturing Market Report 2023-2033

￡ 3,950 ￦ 7,666,000

Unprintable PDF (Single User) - 1 Year License

보고서 PDF를 1명만 이용할 수 있는 라이선스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)로 제공되며, 인증된 PC 1대에서만 열람 가능합니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

￡ 4,500 ￦ 8,733,000

PDF (Team License - Up to 6 Users) - 1 Year License

보고서 PDF를 동일 사업장(소재지) 내의 6명까지 이용할 수 있는 라이선스입니다. PDF 내 텍스트 등의 Copy&Paste는 불가능합니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)이며, 인증된 PC상에서 열람 가능합니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 5,500 ￦ 10,674,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 6,950 ￦ 13,488,000

PDF (Enterprise License - Includes Free Datasets)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 백신 수탁 제조 시장 규모는 2022년에 27억 5,030만 달러로 평가되었습니다. 이 시장은 예측 기간인 2023-2033년간 13.2%의 CAGR로 확대될 것으로 예측됩니다.

세계의 백신 수탁 제조(Vaccine Contract Manufacturing) 시장에 대해 조사했으며, 시장 개요와 함께 공정별/Downstream 공정별/Upstream 공정별/최종 용도별/백신 유형별/운영별/기업 규모별/지역별 동향 및 시장 진출기업 개요 등의 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• PEST 분석

제4장 백신 수탁 제조 시장 분석, 공정별

• 주요 조사 결과
• 적응 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, 공정별
• Upstream 공정
• Downstream 공정

제5장 백신 수탁 제조 시장 분석, Downstream 공정별

• 주요 조사 결과
• Downstream 공정 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, Downstream 공정별
• 충전 및 최종 제제 화
• 분석 및 QC 연구
• 백신 포장

제6장 백신 수탁 제조 시장 분석, Upstream 공정별

• 주요 조사 결과
• Upstream 공정 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, Upstream 공정별
• 포유류 발현 백신 유형
• 세균 발현 백신 유형
• 효모 발현 백신 유형
• Baculovirus/곤충 발현 백신 유형
• 기타 Upstream 공정

제7장 백신 수탁 제조 시장 분석, 최종 용도별

• 주요 조사 결과
• 최종 용도 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, 최종 용도별
• 인간
• 동물

제8장 백신 수탁 제조 시장 분석, 백신 유형별

• 주요 조사 결과
• 백신 유형 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, 백신 유형별
• 아단위 백신
• 약독화 생백신
• 결합 백신
• 불활화 백신
• 톡소이드 백신
• 바이러스 벡터 백신
• 재조합 벡터 백신
• 기타

제9장 백신 수탁 제조 시장 분석, 운영별

• 주요 조사 결과
• 운영 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, 운영 별
• 전임상
• 임상
• 상업

제10장 백신 수탁 제조 시장 분석, 기업 규모별

• 주요 조사 결과
• 기업 규모 부문 : 시장의 매력 지수
• 백신 수탁 제조 시장 규모 추산과 예측, 기업 규모별
• 소규모 제조업체
• 중견 제조업체
• 대형 제조업체
• 초대형 제조업체

제11장 백신 수탁 제조 시장 분석, 지역별

제12장 북미의 백신 수탁 제조 시장 분석

제13장 유럽의 백신 수탁 제조 시장 분석

제14장 아시아태평양의 백신 수탁 제조 시장 분석

제15장 라틴아메리카의 백신 수탁 제조 시장 분석

제16장 중동 및 아프리카의 백신 수탁 제조 시장 분석

제17장 기업 개요

• 경쟁 구도, 2022년
• 전략적 전망
• Catalent, Inc
• Emergent BioSolutions
• Ajinomoto Bio-Pharma
• Lonza
• Curia Global, Inc.
• WuXi Biologics
• Vibalogics
• FUJIFILM Holdings Corporation
• Recipharm AB
• Richter-Helm BioLogics GmbH &Co. KG
• Bavarian Nordic
• Charles River Laboratories
• ICON plc
• Batavia Biosciences B.V.
• IDT Biologika

제18장 결론과 추천 사항

LSH

영문 목차

영문목차

The global Vaccine Contract Manufacturing market was valued at US$2,750.3 million in 2022 and is projected to grow at a CAGR of 13.2% during the forecast period 2023-2033.

"The Vaccine Contract Manufacturing Market Report 2023-2033:" This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Global Demand, Product Innovation and Cost Effectiveness Driving Market Growth

The global demand for vaccines has been rising due to various factors, including population growth, aging populations, and the emergence of infectious diseases. This increasing demand creates opportunities for contract manufacturers to support vaccine developers in meeting the production needs, especially during pandemics or widespread outbreaks. Advances in vaccine research and development have led to the discovery of new vaccines and improved formulations. Contract manufacturers play a crucial role in translating these innovations into commercial products. As vaccine developers focus on R&D activities, they often seek external partners to handle manufacturing operations, driving the demand for contract manufacturing services. Contract manufacturing can provide cost-effective solutions for vaccine production. Establishing and maintaining large-scale manufacturing facilities can be capital-intensive for vaccine developers, while contract manufacturers can leverage their existing infrastructure, equipment, and expertise to produce vaccines at a lower cost per unit. This cost advantage makes contract manufacturing an attractive option for vaccine developers.

Regulations, Intellectual Property and Capacity Challenges to Hamper Industry Growth

The vaccine manufacturing industry is highly regulated, and contract manufacturers need to comply with stringent regulatory requirements imposed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adhering to these regulations can be complex and time-consuming, leading to delays in production and increased costs. Vaccines often involve patented technologies and proprietary manufacturing processes. Contract manufacturers may face limitations or restrictions in accessing or using these technologies due to intellectual property rights held by the vaccine developers. Negotiating licensing agreements and protecting intellectual property can be challenging and may restrict the participation of certain contract manufacturers in the market. The manufacturing capacity for vaccines is limited, and there is often high demand, particularly during pandemics or widespread outbreaks. Contract manufacturers may face challenges in scaling up production to meet the required volumes within tight timelines. Limited capacity can result in delays, supply shortages, and increased competition among contract manufacturers for available projects.

What Questions Should You Ask before Buying a Market Research Report?

• How is the vaccine contract manufacturing market evolving?
• What is driving and restraining the vaccine contract manufacturing market?
• How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each vaccine contract manufacturing submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the vaccine contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of vaccine contract manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
• Where is the vaccine contract manufacturing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the vaccine contract manufacturing market today, and over the next 10 years:

• Our 375-page report provides 143 tables and 229 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the vaccine contract manufacturing market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising vaccine contract manufacturing prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Process

• Upstream Process
• Downstream Process

Downstream Process

• Fill & Finish Operations
• Analytical & QC Studies
• Vaccine Packaging

Upstream Process

• Mammalian Expression Vaccine Type
• Bacterial Expression Vaccine Type
• Yeast Expression Vaccine Type
• Baculovirus/insect Expression Vaccine Type
• Other Upstream Process

End-use

• Human Use
• Veterinary

Type

• Subunit Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Viral Vector Vaccines
• Recombinant Vector Vaccines
• Other Vaccine Types

Operation

• Preclinical
• Clinical
• Commercial

Company Size

• Small Manufacturers
• Mid-sized Manufacturers
• Large Manufacturers
• Very Large Manufacturers

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Vaccine Contract Manufacturing Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Vaccine Contract Manufacturing Market, 2023 to 2033 in terms of value the market will surpass US$3,095.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Vaccine Contract Manufacturing Market, 2023 to 2033 report help you?

In summary, our 370+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Vaccine Contract Manufacturing Market, 2023 to 2033, with forecasts for process, upstream, downstream, end-use, type, operation and company size each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Vaccine Contract Manufacturing Market, 2023 to 2033 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Vaccine Contract Manufacturing Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the vaccine contract manufacturing market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Vaccine Contract Manufacturing Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Reports
• 1.10 About

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Growth in infectious diseases
    • 3.2.1.2 Stakeholder cooperation maximises manufacturing capacity
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Material and equipment shortages
    • 3.2.2.2 Manufacturing process complexity
  • 3.2.3 Market Opportunities
    • 3.2.3.1 New vaccine technologies
    • 3.2.3.2 Gene-based vaccines
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Vaccine Contract Manufacturing Market Analysis by Process

• 4.1 Key Findings
• 4.2 Indication Segment: Market Attractiveness Index
• 4.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 4.4 Upstream Process
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Downstream Process
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Vaccine Contract Manufacturing Market Analysis by Downstream Process

• 5.1 Key Findings
• 5.2 Downstream Process Segment: Market Attractiveness Index
• 5.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 5.4 Fill & Finish Operations
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Analytical & QC Studies
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Vaccine Packaging
  • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Vaccine Contract Manufacturing Market Analysis by Upstream Process

• 6.1 Key Findings
• 6.2 Upstream Process Segment: Market Attractiveness Index
• 6.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 6.4 Mammalian Expression Vaccine Type
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Bacterial Expression Vaccine Type
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)
• 6.6 Yeast Expression Vaccine Type
  • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.6.2 Market Share by Region, 2023 & 2033 (%)
• 6.7 Baculovirus/insect Expression Vaccine Type
  • 6.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.7.2 Market Share by Region, 2023 & 2033 (%)
• 6.8 Other Upstream Process
  • 6.8.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.8.2 Market Share by Region, 2023 & 2033 (%)

7 Vaccine Contract Manufacturing Market Analysis by End-use

• 7.1 Key Findings
• 7.2 End-use Segment: Market Attractiveness Index
• 7.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
• 7.4 Human Use
  • 7.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 7.4.2 Market Share by Region, 2023 & 2033 (%)
• 7.5 Veterinary
  • 7.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 7.5.2 Market Share by Region, 2023 & 2033 (%)

8 Vaccine Contract Manufacturing Market Analysis by Vaccine Type

• 8.1 Key Findings
• 8.2 Vaccine Type Segment: Market Attractiveness Index
• 8.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 8.4 Subunit Vaccines
  • 8.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.4.2 Market Share by Region, 2023 & 2033 (%)
• 8.5 Live Attenuated Vaccines
  • 8.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.5.2 Market Share by Region, 2023 & 2033 (%)
• 8.6 Conjugate Vaccines
  • 8.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.6.2 Market Share by Region, 2023 & 2033 (%)
• 8.7 Inactivated Vaccines
  • 8.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.7.2 Market Share by Region, 2023 & 2033 (%)
• 8.8 Toxoid Vaccines
  • 8.8.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.8.2 Market Share by Region, 2023 & 2033 (%)
• 8.9 Viral Vector Vaccines
  • 8.9.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.9.2 Market Share by Region, 2023 & 2033 (%)
• 8.10 Recombinant Vector Vaccines
  • 8.10.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.10.2 Market Share by Region, 2023 & 2033 (%)
• 8.11 Other Vaccine Types
  • 8.11.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.11.2 Market Share by Region, 2023 & 2033 (%)

9 Vaccine Contract Manufacturing Market Analysis by Operation

• 9.1 Key Findings
• 9.2 Operation Segment: Market Attractiveness Index
• 9.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 9.4 Preclinical
  • 9.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 9.4.2 Market Share by Region, 2023 & 2033 (%)
• 9.5 Clinical
  • 9.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 9.5.2 Market Share by Region, 2023 & 2033 (%)
• 9.6 Commercial
  • 9.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 9.6.2 Market Share by Region, 2023 & 2033 (%)

10 Vaccine Contract Manufacturing Market Analysis by Company Size

• 10.1 Key Findings
• 10.2 Company Size Segment: Market Attractiveness Index
• 10.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 10.4 Small Manufacturers
  • 10.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 10.4.2 Market Share by Region, 2023 & 2033 (%)
• 10.5 Mid-sized Manufacturers
  • 10.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 10.5.2 Market Share by Region, 2023 & 2033 (%)
• 10.6 Large Manufacturers
  • 10.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 10.6.2 Market Share by Region, 2023 & 2033 (%)
• 10.7 Very Large Manufacturers
  • 10.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 10.7.2 Market Share by Region, 2023 & 2033 (%)

11 Vaccine Contract Manufacturing Market Analysis by Region

• 11.1 Key Findings
• 11.2 Regional Market Size Estimation and Forecast

12 North America Vaccine Contract Manufacturing Market Analysis

• 12.1 Key Findings
• 12.2 North America Vaccine Contract Manufacturing Market Attractiveness Index
• 12.3 North America Vaccine Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 12.4 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
• 12.5 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 12.6 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 12.7 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 12.8 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-users
• 12.9 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 12.10 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 12.11 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 12.12 U.S. Vaccine Contract Manufacturing Market Analysis
• 12.13 Canada Vaccine Contract Manufacturing Market Analysis

13 Europe Vaccine Contract Manufacturing Market Analysis

• 13.1 Key Findings
• 13.2 Europe Vaccine Contract Manufacturing Market Attractiveness Index
• 13.3 Europe Vaccine Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 13.4 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
• 13.5 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 13.6 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 13.7 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 13.8 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-users
• 13.9 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 13.10 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 13.11 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 13.12 Germany Vaccine Contract Manufacturing Market Analysis
• 13.13 UK Vaccine Contract Manufacturing Market Analysis
• 13.14 France Vaccine Contract Manufacturing Market Analysis
• 13.15 Italy Vaccine Contract Manufacturing Market Analysis
• 13.16 Spain Vaccine Contract Manufacturing Market Analysis
• 13.17 Russia Vaccine Contract Manufacturing Market Analysis
• 13.18 Rest of Europe Vaccine Contract Manufacturing Market Analysis

14 Asia Pacific Vaccine Contract Manufacturing Market Analysis

• 14.1 Key Findings
• 14.2 Asia Pacific Vaccine Contract Manufacturing Market Attractiveness Index
• 14.3 Asia Pacific Vaccine Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 14.4 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
• 14.5 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 14.6 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 14.7 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 14.8 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-users
• 14.9 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 14.10 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 14.11 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 14.12 China Vaccine Contract Manufacturing Market Analysis
• 14.13 India Vaccine Contract Manufacturing Market Analysis
• 14.14 Japan Vaccine Contract Manufacturing Market Analysis
• 14.15 South Korea Vaccine Contract Manufacturing Market Analysis
• 14.16 Australia Vaccine Contract Manufacturing Market Analysis
• 14.17 Rest of Asia-Pacific Vaccine Contract Manufacturing Market Analysis

15 Latin America Vaccine Contract Manufacturing Market Analysis

• 15.1 Key Findings
• 15.2 Latin America Vaccine Contract Manufacturing Market Attractiveness Index
• 15.3 Latin America Vaccine Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 15.4 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
• 15.5 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 15.6 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 15.7 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 15.8 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-users
• 15.9 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 15.10 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 15.11 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 15.12 Brazil Vaccine Contract Manufacturing Market Analysis
• 15.13 Mexico Vaccine Contract Manufacturing Market Analysis
• 15.14 Rest of Latin America Vaccine Contract Manufacturing Market Analysis

16 Middle East & Africa Vaccine Contract Manufacturing Market Analysis

• 16.1 Key Findings
• 16.2 Middle East & Africa Vaccine Contract Manufacturing Market Attractiveness Index
• 16.3 Middle East & Africa Vaccine Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 16.4 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
• 16.5 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
• 16.6 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Downstream Process
• 16.7 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Upstream Process
• 16.8 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-users
• 16.9 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Vaccine Type
• 16.10 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
• 16.11 Middle East & Africa Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
• 16.12 GCC Vaccine Contract Manufacturing Market Analysis
• 16.13 South Africa Vaccine Contract Manufacturing Market Analysis
• 16.14 Rest of MEA Vaccine Contract Manufacturing Market Analysis

17 Company Profiles

• 17.1 Competitive Landscape, 2022
• 17.2 Strategic Outlook
• 17.3 Catalent, Inc
  • 17.3.1 Company Snapshot
  • 17.3.2 Company Overview
  • 17.3.3 Financial Analysis
    • 17.3.3.1 Net Revenue, 2017-2022
    • 17.3.3.2 Regional Market Shares, 2022
  • 17.3.4 Service Benchmarking
  • 17.3.5 Strategic Outlook
• 17.4 Emergent BioSolutions
  • 17.4.1 Company Snapshot
  • 17.4.2 Company Overview
  • 17.4.3 Financial Analysis
    • 17.4.3.1 Net Revenue, 2017-2022
    • 17.4.3.2 R&D, 2017-2022
    • 17.4.3.3 Regional Market Shares, 2022
  • 17.4.4 Service Benchmarking
  • 17.4.5 Strategic Outlook
• 17.5 Ajinomoto Bio-Pharma
  • 17.5.1 Company Snapshot
  • 17.5.2 Company Overview
  • 17.5.3 Financial Analysis
    • 17.5.3.1 Net Revenue, 2017-2022
    • 17.5.3.2 Regional Market Shares, 2022
  • 17.5.4 Service Benchmarking
  • 17.5.5 Strategic Outlook
• 17.6 Lonza
  • 17.6.1 Company Snapshot
  • 17.6.2 Company Overview
  • 17.6.3 Financial Analysis
    • 17.6.3.1 Net Revenue, 2017-2022
    • 17.6.3.2 R&D, 2017-2022
    • 17.6.3.3 Regional Market Shares, 2022
  • 17.6.4 Service Benchmarking
  • 17.6.5 Strategic Outlook
• 17.7 Curia Global, Inc.
  • 17.7.1 Company Snapshot
  • 17.7.2 Company Overview
  • 17.7.3 Service Benchmarking
  • 17.7.4 Strategic Outlook
• 17.8 WuXi Biologics
  • 17.8.1 Company Snapshot
  • 17.8.2 Company Overview
  • 17.8.3 Financial Analysis
    • 17.8.3.1 Net Revenue, 2017-2022
    • 17.8.3.2 R&D, 2017-2022
    • 17.8.3.3 Regional Market Shares, 2022
  • 17.8.4 Service Benchmarking
  • 17.8.5 Strategic Outlook
• 17.9 Vibalogics
  • 17.9.1 Company Snapshot
  • 17.9.2 Company Overview
  • 17.9.3 Service Benchmarking
  • 17.9.4 Strategic Outlook
• 17.10 FUJIFILM Holdings Corporation
  • 17.10.1 Company Snapshot
  • 17.10.2 Company Overview
  • 17.10.3 Financial Analysis
    • 17.10.3.1 Net Revenue, 2017-2022
    • 17.10.3.2 R&D, 2017-2022
    • 17.10.3.3 Regional Market Shares, 2022
  • 17.10.4 Service Benchmarking
• 17.11 Recipharm AB
  • 17.11.1 Company Snapshot
  • 17.11.2 Company Overview
  • 17.11.3 Service Benchmarking
  • 17.11.4 Strategic Outlook
• 17.12 Richter-Helm BioLogics GmbH & Co. KG
  • 17.12.1 Company Snapshot
  • 17.12.2 Company Overview
  • 17.12.3 Service Benchmarking
  • 17.12.4 Strategic Outlook
• 17.13 Bavarian Nordic
  • 17.13.1 Company Snapshot
  • 17.13.2 Company Overview
  • 17.13.3 Financial Analysis
    • 17.13.3.1 Net Revenue, 2017-2022
    • 17.13.3.2 R&D, 2017-2022
  • 17.13.4 Service Benchmarking
• 17.14 Charles River Laboratories
  • 17.14.1 Company Snapshot
  • 17.14.2 Company Overview
  • 17.14.3 Financial Analysis
    • 17.14.3.1 Net Revenue, 2017-2022
    • 17.14.3.2 Regional Market Shares, 2022
  • 17.14.4 Service Benchmarking
  • 17.14.5 Strategic Outlook
• 17.15 ICON plc
  • 17.15.1 Company Snapshot
  • 17.15.2 Company Overview
  • 17.15.3 Financial Analysis
    • 17.15.3.1 Net Revenue, 2017-2022
    • 17.15.3.2 R&D, 2017-2022
    • 17.15.3.3 Regional Market Shares, 2022
  • 17.15.4 Service Benchmarking
  • 17.15.5 Strategic Outlook
• 17.16 Batavia Biosciences B.V.
  • 17.16.1 Company Snapshot
  • 17.16.2 Company Overview
  • 17.16.3 Service Benchmarking
• 17.17 IDT Biologika
  • 17.17.1 Company Snapshot
  • 17.17.2 Company Overview
  • 17.17.3 Service Benchmarking

18 Conclusion and Recommendations

• 18.1 Concluding Remarks from
• 18.2 Recommendations for Market Players

관련자료